The Food and Drug Administration (FDA) has given its approval for the clinical trials of Lagundi, a familiar local herb, “as a mode of adjuvant therapy.”
The clinical trials will be conducted under the auspices of the Department of Science and Technology (DOST) The projects aims “to determine if lagundi, as an adjuvant therapy medium, can provide symptomatic relief for mild Covid-19 infection without co-morbidities.”
DOST Secretary Fortunato de la Peña said the clinical trial needs FDA approval as it will “further evaluate and ensure full protection of human subjects’ rights and safety, and the integrity of clinical trial data through the adoption and implementation of international standards on good clinical practice.”
Three quarantine centers have agreed to participate in clinical trials on lagundi — the Quezon Institute Quarantine Center, Sta. Ana Hospital in Manila, and PNP-NCR Community Quarantine Center.
De la Pena said their project team has also coordinated with selected community quarantine centers where the study shall be conducted. He, however, has not mentioned any number of their target participants.
The study, he explained, also aims to determine if lagundi can decrease the number of patients who progress from mild to moderate or severe cases.
Lagundi medicinal preparations – tablet or syrup – have been proven as effective bronchodilators and treatment for cough and related common symptoms of Covid-19 which include fever, sore throat, myalgia, and fatigue.
De la Pena noted that because of these pharmacological properties, lagundi seems a suitable choice for the symptomatic treatment of Covid-19 patients.